Cyclobenzaprine Hydrochloride Tablet, Film Coated
Product Images NDC 51655-973

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Cyclobenzaprine Hydrochloride (NDC 51655-973). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northwind Health Company, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (51655 973 87 Master Bottle Label Approval Rev A 05 22)

Label (51655 973 87 Master Bottle Label Approval   Rev A 05 22)
Packaging label for Cyclobenzaprine Hydrochloride Tablets, USP 10 mg, film-coated, containing 6 tablets. The label states the product is prescription only, with storage instructions at controlled room temperature. The labeler is Northwind Pharmaceuticals, under Northwind Health Company, LLC.*
FDA Label Image

Image (7d5e3bad 7f85 4e2b 81c5 7981c456e45f 01)

Image (7d5e3bad 7f85 4e2b 81c5 7981c456e45f 01)
Chemical structure of Cyclobenzaprine Hydrochloride, showing the molecular arrangement with aromatic rings and functional groups including dimethylamino and hydrochloride components.*
FDA Label Image

Image (7d5e3bad 7f85 4e2b 81c5 7981c456e45f 02)

Image (7d5e3bad 7f85 4e2b 81c5 7981c456e45f 02)
A table comparing the incidence of side effects including drowsiness, dry mouth, fatigue, and headache among patients treated with Cyclobenzaprine HCl tablets at 5 mg and 10 mg doses versus placebo. The data shows percentages for each side effect within each group, illustrating higher rates of drowsiness and dry mouth in Cyclobenzaprine groups compared to placebo.*
FDA Label Image

Image (7d5e3bad 7f85 4e2b 81c5 7981c456e45f 03)

Image (7d5e3bad 7f85 4e2b 81c5 7981c456e45f 03)
Table comparing adverse event frequencies in clinical studies versus a surveillance program for Cyclobenzaprine Hydrochloride 10 mg tablets. It lists percentages for drowsiness, dry mouth, and dizziness in both study types.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.